The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
In a recent podcast episode, Jack Andrews, MD, discussed the role of PSMA PET in facilitating more targeted, metastasis-directed therapy for prostate cancer and recent phase 4 research comparing PSMA PET agents in men with low PSA values.
In a recent episode of our Molecular Imaging in Focus series, Christopher Rowe, MD, BMBS, FRACP, FAANMS, discussed pertinent phase 3 study findings for florquinitau F 18 that were presented at the recent Clinical Trials on Alzheimer’s Disease conference.
In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),
In a new podcast episode, Sharmila Dorbala, MD, MPH, shares her insights on recently published phase 3 research examining the use of the PET/CT radiotracer 124I-evuzamitide for bolstering detection of cardiac amyloidosis.
The a2z-Omni-Triage software reportedly facilitates adjunctive triage for a number of findings including pneumothorax, coccygeal fracture, bowel perforation and moderate or severe hydronephrosis.